The CAMELOT (Comparison of Amlodipine vs Enalapril to Limit Occurrences of Thrombosis) trial shows amlodipine besylate significantly reduces major cardiovasular events in patients with coronary heart disease.
RESULTS of a drug trial reveal that the blood pressure-lowering medicine amlodipine besylate had 31% fewer major cardiovascular events compared to patients who received standard care. The results were published recently in the November issue of the Journal of the American Medical Association.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
